News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Abivax
< Previous
1
2
Next >
Abivax Announces Full Year 2024 Financial Results
March 24, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
February 21, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Publishes 2025 Financial Calendar
January 28, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
January 23, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
January 09, 2025
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces a Change to the Composition of its Board of Directors
December 23, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
November 19, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax presents third quarter 2024 key financial information
November 14, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
November 13, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
October 07, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
October 03, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
October 03, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
September 26, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
September 25, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax presents first-half 2024 financial results
September 09, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
August 06, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax Provides Operational and Key Program Update
July 15, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
June 04, 2024
From
Abivax
Via
GlobeNewswire
Tickers
ABVX
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
May 08, 2024
From
Abivax
Via
GlobeNewswire
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
May 07, 2024
From
Abivax
Via
GlobeNewswire
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
April 05, 2024
From
Abivax
Via
GlobeNewswire
Abivax reports 2023 financial results and operational update
April 02, 2024
From
Abivax
Via
GlobeNewswire
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
February 07, 2024
From
Abivax
Via
GlobeNewswire
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
February 02, 2024
From
Abivax
Via
GlobeNewswire
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
January 24, 2024
From
Abivax
Via
GlobeNewswire
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
January 22, 2024
From
Abivax
Via
GlobeNewswire
Abivax 2024 Financial Communication Calendar
January 04, 2024
From
Abivax
Via
GlobeNewswire
Abivax announces the resumption of its liquidity contract
November 21, 2023
From
Abivax
Via
GlobeNewswire
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From
Abivax
Via
GlobeNewswire
Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting
June 10, 2022
From
ABIVAX
Via
AccessWire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
